Company: ARTL
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0001640334-25-000335
Chunk: 248

Company: ARTELO BIOSCIENCES, INC.
Filing Date: 2025-03-03
Form: 10-K
Item: Item 1A
Chunk 248
---
 on our success in many areas, including:

 ·our research and development efforts, including preclinical studies and clinical trials of our product candidates;    ·developing sustainable, scalable, reliable and cost-effective manufacturing and distribution processes for our product candidates, including establishing and maintaining commercially viable supply relationships with third parties and establishing our own cGMPs, manufacturing facilities and processes;    ·addressing any competing technological and industry developments;    ·identifying, assessing, acquiring and/or developing new technology platforms and product candidates across numerous therapeutic areas;    ·obtaining regulatory approvals and marketing authorizations for product candidates;    ·launching and commercializing any approved products, either directly or with a collaborator or distributor;    ·obtaining market acceptance of and acceptable reimbursement for any approved products;    ·completing collaborations, licenses and other strategic transactions on favorable terms, if at all;    ·maintaining, protecting and expanding our portfolio of intellectual property rights, including patents, trade secrets and know-how; and    ·attracting, hiring and retaining qualified personnel.

The Company has very limited operating history and capabilities.

Although our company was formed in 2011, our current business focus and operations in pharmaceutical development began in 2017. The Company does not currently have the ability to perform all the functions necessary to develop and commercialize any product candidates. The successful development of any product candidates will require us to perform a variety of functions including, but not limited to:

·identifying, licensing and obtaining development programs and lead candidates; ·conducting initial research required to identify a lead candidate as the result of intellectual property the Company has licensed; ·initiating preclinical, clinical or other required studies for future product candidates; ·adding manufacturers and suppliers required to advance our programs; ·obtaining regulatory and marketing approvals for our product candidates that successfully complete clinical studies; ·making milestone or other payments under any license agreements; ·expanding, maintaining and protecting our intellectual property portfolio; ·attracting and retaining skilled personnel; and ·creating and maintaining an infrastructure required to support our operations as a public company.

 26Table of contents

Our operations continue to be focused on acquiring, developing and securing our proprietary technology and undertaking preclinical and clinical trials of our products.

The Company expects our financial condition and operating results to continue to fluctuate from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control